Journal article
Chemoradiotherapy With or Without AE-941 in Stage III Non–Small Cell Lung Cancer: A Randomized Phase III Trial
Abstract
BACKGROUND AE-941 is a standardized aqueous shark cartilage extract with antiangiogenic properties that has previously been evaluated in phase I and II clinical trials. Our objective was to determine the effect of adding AE-941 to chemoradiotherapy on overall survival of patients with unresectable stage III non-small cell lung cancer (NSCLC). METHODS A randomized, double-blinded, placebo-controlled, phase III clinical trial was designed to test …
Authors
Lu C; Lee JJ; Komaki R; Herbst RS; Feng L; Evans WK; Choy H; Desjardins P; Esparaz BT; Truong MT
Journal
Journal of the National Cancer Institute, Vol. 102, No. 12, pp. 859–865
Publisher
Oxford University Press (OUP)
Publication Date
June 16, 2010
DOI
10.1093/jnci/djq179
ISSN
0027-8874
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAngiogenesis InhibitorsAntineoplastic Combined Chemotherapy ProtocolsBiological ProductsCarcinoma, Non-Small-Cell LungCartilageChemotherapy, AdjuvantDisease-Free SurvivalDouble-Blind MethodFemaleHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedMultivariate AnalysisNeoplasm StagingRadiotherapy, AdjuvantTissue ExtractsTreatment Outcome